Viehbacher Christopher 4

What Happened

• Christopher Viehbacher, President & CEO and a director of Biogen, had restricted stock units convert into common shares on 2026-02-06 (two conversion events totaling 24,461 shares at $0.00 exercise price). To cover tax withholding, 10,980 of those shares were surrendered/sold at $201.18 per share, producing proceeds of $2,208,956. The remaining net shares retained from the conversions were 13,481.

Key Details

• Transaction date: February 6, 2026; Form 4 filed February 10, 2026 (timely within the 2 business-day requirement).
• Conversions (code M): 9,008 and 15,453 shares acquired at $0.00 (total 24,461).
• Withholding/disposals (code F): 4,356 and 6,624 shares disposed at $201.18 (total 10,980), total proceeds $2,208,956.
• Net shares retained after withholding: 13,481 (24,461 converted − 10,980 withheld).
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• Footnotes: F1 and F2 indicate these were restricted stock units vesting in three equal annual installments (grants dated 02/07/2024 and 02/06/2025, respectively).
• No late-filing indicator or 10b5‑1 plan was noted in the provided filing excerpt.

Context

• The filings reflect RSU vesting and a standard "sell-to-cover" / tax-withholding action (exercise/conversion of RSUs followed by share surrender/sale to satisfy tax liability). This is a common administrative transaction and not necessarily a directional buy/sell signal about company prospects.